Tag: ibdoc

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is Not Available for Sale in the US.
Continue Reading

IBDoc Learning with Video Tutorials

New IBDoc® Tutorials (available on: ibdoc.net) IBDoc® Portal Tutorial videos offer: Quick and easy training for the sites to learn the important portal functionalities Updated healthcare professional and patient training Who Are the Videos for? Clinical Administrators Clinical Users View these six new IBDoc® Portal Tutorial Videos. They are geared toward helping Healthcare Professionals that
Continue Reading

Patient’s Perspective- One Year using IBDoc

Read a recent article written from the perspective of a long term Crohn's sufferer who shares his experience of managing the disease with the help of calprotectin self-testing. Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories. Highlight from this Perspective Article “It has reduced the “waiting time” for results down to hours instead of days or
Continue Reading

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,”  Associate Professor
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading

Connect with BUHLMANN at CDDW 2018 in Toronto

Canadian Digestive Diseases Week (CDDW) 2018 BUHLMANN Diagnostics Corp  Booth: #135 Feb 09 - 11, 2018 | The Fairmont Royal York | Toronto, ON Learn More Come by our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the ONLY in-vitro diagnostic POC and home testing device to measure the inflammatory marker,
Continue Reading

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846. Highlights from this Publication “… we showed that the smartphone reader used by patients
Continue Reading

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between
Continue Reading